Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 43

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Breast cancer female

Not yet recruiting

Study on the Use of Iomeprol in Contrast Enhanced Mammography for Identifying Breast Cancer in Patients with BIRADS 4 or 5 Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Iomeprol
  • Sponsor:Azienda Ospedaliero-Universitaria Policlinico Umberto I

Malignant peritoneal neoplasm+2

Not yet recruiting

Study on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Agencja Badań Medycznych

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hormone receptor positive breast cancer

Not yet recruiting

Study on Cannabidiol for Joint Pain in Early Breast Cancer Patients on Hormone Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cannabidiol
  • Sponsor:Institut Gustave Roussy

Breast cancer

Not yet recruiting

Study on the Effectiveness of Ropivacaine Hydrochloride, Anhydrous Lidocaine Hydrochloride, and Alfentanil for Patients Undergoing Minor Breast Cancer Surgery

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Lidocaine Hydrochloride
  • Sponsor:Region Sjaelland

Endometriosis

Not yet recruiting

Study on Cabergoline for Pain and Fertility in Women with Endometriosis and Infertility

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Cabergoline
  • Sponsor:Turku University Hospital

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Triple negative breast cancer

Not yet recruiting

Study on Early Detection of Triple-Negative Breast Cancer Relapse Using [68Ga]Ga-FAPI-46 for Patients at High Risk

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Institut Curie

Immunoglobulin G4 related disease+3

Not yet recruiting

Study on the Safety and Effectiveness of Filgotinib for Patients with Refractory Behcet's Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Infertility

Not yet recruiting

Study on Progesterone and Estradiol for Infertility in Patients Undergoing Hormone Replacement Therapy with Frozen Embryo Transfer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Estradiol
  • Sponsor:Region Midtjylland

Triple negative breast cancer

Not yet recruiting

Study of ipatasertib with atezolizumab and chemotherapy in women with triple-negative breast cancer before surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Queen Mary University Of London

Acute leukaemia+6

Not yet recruiting

Study on Triptorelin for Fertility Protection in Young Women and Teenagers Undergoing Chemotherapy for Breast Cancer, Leukemia, Lymphomas, and Sarcomas

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Triptorelin
  • Sponsor:Karolinska University Hospital

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.